PTPRJ — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2401972	1.00	1/20
SCHEMBL13738901	1.00	1/20
SCHEMBL13738903	1.00	1/20
SCHEMBL14154415	1.00	1/20
SCHEMBL29391398	1.00	1/20
SCHEMBL30542884	1.00	1/20
SCHEMBL2401966	0.98	1/20
SCHEMBL18874952	0.79	1/20
SCHEMBL391667	0.76	1/20
SCHEMBL2401970	0.76	1/20
SCHEMBL31186847	0.76	1/20
SCHEMBL13936092	0.73	1/20
SCHEMBL11452507	0.71	1/20
SCHEMBL14111957	0.71	1/20
SCHEMBL4599826	0.69	1/20
SCHEMBL13856924	0.69	1/20
SCHEMBL13934931	0.69	1/20
SCHEMBL13936087	0.68	1/20
SCHEMBL13921606	0.68	1/20
SCHEMBL13921609	0.67	1/20

Clinical trials — most relevant to PTPRJ by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP	PHASE1/PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population	PHASE2	ACTIVE_NOT_RECRUITING
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPRJ binder may also engage these)

Protein	Name	Similarity
Q64455	—	0.996	Q64455 →
Q9WVT0	—	0.990	Q9WVT0 →
PTPRO	Receptor-type tyrosine-protein phosphatase O	0.989	landscape →
P04157	—	0.989	P04157 →
Q8IZF2	—	0.988	Q8IZF2 →
G5E8Q8	—	0.987	G5E8Q8 →
Q96PD2	—	0.987	Q96PD2 →
Q66607	—	0.987	Q66607 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.987	landscape →
E9Q612	—	0.986	E9Q612 →
P22080	—	0.986	P22080 →
B0CLX4	—	0.986	B0CLX4 →
Q9D7L8	—	0.986	Q9D7L8 →
P22596	—	0.985	P22596 →
O18016	—	0.985	O18016 →
Q92729	—	0.985	Q92729 →
P52583	—	0.985	P52583 →
P28986	—	0.985	P28986 →
P19617	—	0.984	P19617 →
PTPRC	Receptor-type tyrosine-protein phosphatase C	0.984	landscape →
Q3T113	—	0.984	Q3T113 →
P35054	—	0.984	P35054 →
P03228	—	0.984	P03228 →
Q9H6D8	—	0.984	Q9H6D8 →
P22650	—	0.984	P22650 →
P0CW72	—	0.984	P0CW72 →
Q5GIT4	—	0.984	Q5GIT4 →
Q9R097	—	0.984	Q9R097 →
P33500	—	0.984	P33500 →
Q9Z0T6	—	0.984	Q9Z0T6 →